{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:20:13Z","timestamp":1785327613877,"version":"3.55.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Enfortumab vedotin (EV) is an established pharmacotherapy for metastatic urothelial carcinoma (mUC); however, its adverse events (AEs) cannot be overlooked. The study investigated the efficacy and safety of biweekly EV administration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with mUC who received EV at our institution were included in the study. Eligible patients were classified into two groups as follows: those who received EV on a standard schedule (standard group) and those who received EV on a biweekly schedule (biweekly group); the treatment outcomes and AEs between the two groups were compared.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Nine and 19 patients were in the standard group and biweekly groups, respectively. The progression-free survival, overall survival, and overall response rate were not significantly different between the two groups. AEs following EV administration, such as decreased appetite (P\u00a0&amp;lt;\u00a0.01), pruritus (P\u00a0&amp;lt;\u00a0.01), rash maculopapular (P\u00a0&amp;lt;\u00a0.01), anemia (P\u00a0=\u00a0.04), and liver dysfunction (P\u00a0=\u00a0.04), were significantly more frequent in the standard group. Grade 3 or higher AEs, such as pruritus (P\u00a0=\u00a0.03) and rash maculopapular (P\u00a0&amp;lt;\u00a0.01), were significantly more frequent in the standard group. Furthermore, significantly more patients in the standard group had to be given a reduced dose due to adverse events (P\u00a0=\u00a0.02).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Biweekly administration of EV may be safer without compromising therapeutic efficacy than the standard schedule.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyae101","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T19:52:48Z","timestamp":1722369168000},"page":"1329-1335","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic efficacy and safety of biweekly administration of enfortumab vedotin for urothelial carcinoma"],"prefix":"10.1093","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2503-8908","authenticated-orcid":false,"given":"Ryunosuke","family":"Nakagawa","sequence":"first","affiliation":[{"name":"Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science , Kanazawa, Ishikawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouji","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science , Kanazawa, Ishikawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Toriumi","sequence":"additional","affiliation":[{"name":"Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science , Kanazawa, Ishikawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Aoyama","sequence":"additional","affiliation":[{"name":"Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science , Kanazawa, Ishikawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Kamijima","sequence":"additional","affiliation":[{"name":"Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science , Kanazawa, Ishikawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kano","sequence":"additional","affiliation":[{"name":"Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science , Kanazawa, Ishikawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Makino","sequence":"additional","affiliation":[{"name":"Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science , Kanazawa, Ishikawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Naito","sequence":"additional","affiliation":[{"name":"Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science , Kanazawa, Ishikawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3599-2217","authenticated-orcid":false,"given":"Hiroaki","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science , Kanazawa, Ishikawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3188-8834","authenticated-orcid":false,"given":"Hiroshi","family":"Yaegashi","sequence":"additional","affiliation":[{"name":"Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science , Kanazawa, Ishikawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6847-9861","authenticated-orcid":false,"given":"Shohei","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science , Kanazawa, Ishikawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Shigehara","sequence":"additional","affiliation":[{"name":"Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science , Kanazawa, Ishikawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nohara","sequence":"additional","affiliation":[{"name":"Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science , Kanazawa, Ishikawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Mizokami","sequence":"additional","affiliation":[{"name":"Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science , Kanazawa, Ishikawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"2024121023184999400_ref1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"2024121023184999400_ref2","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN Guidelines\u00ae Insights: Bladder Cancer, Version 2.2022","volume":"20","author":"Flaig","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2024121023184999400_ref3","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7","article-title":"Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse","volume":"64","author":"Sternberg","year":"1989","journal-title":"Cancer"},{"key":"2024121023184999400_ref4","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"2024121023184999400_ref5","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"2024121023184999400_ref6","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"2024121023184999400_ref7","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/iju.15300","article-title":"Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study","volume":"30","author":"Taguchi","year":"2023","journal-title":"Int J Urol"},{"key":"2024121023184999400_ref8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/jjco\/hyad170","article-title":"Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort","volume":"54","author":"Miyake","year":"2023","journal-title":"Jpn J Clin Oncol"},{"key":"2024121023184999400_ref9","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/cam4.5165","article-title":"Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma","volume":"12","author":"Matsubara","year":"2023","journal-title":"Cancer Med"},{"key":"2024121023184999400_ref10","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: A phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024121023184999400_ref11","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"2024121023184999400_ref12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1467-2494.2006.00302.x","article-title":"Ethnic skin types: are there differences in skin structure and function?","volume":"28","author":"Rawlings","year":"2006","journal-title":"Int J Cosmet Sci"},{"key":"2024121023184999400_ref13","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamadermatol.2021.3450","article-title":"Postmarketing cases of enfortumab vedotin-associated skin reactions reported as Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"157","author":"Nguyen","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2024121023184999400_ref14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/iju5.12562","article-title":"Toxic epidermal necrolysis after the administration of enfortumab vedotin for urinary bladder urothelial carcinoma","volume":"6","author":"Mimura","year":"2023","journal-title":"IJU Case Rep"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/12\/1329\/60983187\/hyae101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/12\/1329\/60983187\/hyae101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T23:19:36Z","timestamp":1733872776000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/12\/1329\/7723798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":14,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,7,30]]},"published-print":{"date-parts":[[2024,12,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae101","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,7,30]]}}}